{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:26Z","timestamp":1789140686947,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40123-025-01233-9","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:55:40Z","timestamp":1758272140000},"page":"2623-2629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Does the Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema in Randomized Trials Translate into Real-World Settings?"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-0381","authenticated-orcid":false,"given":"Tunde","family":"Peto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-9967","authenticated-orcid":false,"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7467-9947","authenticated-orcid":false,"given":"Veeral","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-239X","authenticated-orcid":false,"given":"Andreas","family":"Pollreisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"1233_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1077669","volume":"13","author":"TE Tan","year":"2022","unstructured":"Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030. Front Endocrinol (Lausanne). 2022;13:1077669.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1233_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"TA Ciulla","year":"2021","unstructured":"Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2021;105(2):216\u201321.","journal-title":"Br J Ophthalmol"},{"key":"1233_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939\u201346.","journal-title":"Clin Ophthalmol"},{"issue":"10326","key":"1233_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, Phase 3 Trials. Lancet. 2022;399(10326):741\u201355.","journal-title":"Lancet"},{"issue":"6","key":"1233_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"issue":"8","key":"1233_CR6","first-page":"2387","volume":"66","author":"MA Singer","year":"2025","unstructured":"Singer MA, Khanani AM, Abreu F, Gibson K, Kotak A, Lai TYY, et al. Update on faricimab for DME: new clinical features of eyes in the RHONE-X study. Invest Ophthalmol Vis Sci. 2025;66(8):2387.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1233_CR7","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2(12):1179\u201387.","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"1233_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","volume":"127","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Wells JA, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T extension study). Ophthalmology. 2020;127(9):1201\u201310.","journal-title":"Ophthalmology"},{"issue":"4","key":"1233_CR9","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.xops.2025.100744","volume":"5","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Guymer R, Artignan A, Downey A, Singh RP. Real-world evidence for faricimab in neovascular age-related macular degeneration and diabetic macular edema: a scoping review. Ophthalmol Sci. 2025;5(4):100744.","journal-title":"Ophthalmol Sci"},{"issue":"9","key":"1233_CR10","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/bjo-2023-324394","volume":"108","author":"AF Durrani","year":"2024","unstructured":"Durrani AF, Momenaei B, Wakabayashi T, Vemula S, Pandit SA, Hsu J, et al. Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema. Br J Ophthalmol. 2024;108(9):1257\u201362.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1233_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280488","volume":"18","author":"T Tsai","year":"2023","unstructured":"Tsai T, Alwees M, Asaad MA, Theile J, Kakkassery V, Dick HB, et al. Increased angiopoietin-1 and -2 levels in human vitreous are associated with proliferative diabetic retinopathy. PLoS One. 2023;18(1): e0280488.","journal-title":"PLoS One"},{"issue":"4","key":"1233_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/medicina59040665","volume":"59","author":"S Kusuhara","year":"2023","unstructured":"Kusuhara S, Kishimoto-Kishi M, Matsumiya W, Miki A, Imai H, Nakamura M. Short-term outcomes of intravitreal faricimab injection for diabetic macular edema. Medicina. 2023;59(4):665.","journal-title":"Medicina"},{"issue":"6","key":"1233_CR13","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3390\/medicina59061125","volume":"59","author":"H Ohara","year":"2023","unstructured":"Ohara H, Harada Y, Hiyama T, Sadahide A, Minamoto A, Kiuchi Y. Faricimab for diabetic macular edema in patients refractory to ranibizumab or aflibercept. Medicina. 2023;59(6):1125.","journal-title":"Medicina"},{"key":"1233_CR14","doi-asserted-by":"crossref","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388.","DOI":"10.15252\/emmm.201505889"},{"key":"1233_CR15","doi-asserted-by":"crossref","unstructured":"Goldberg RA, Mar FA, Csaky K, Amador M, Khanani AM, Gibson K, et al. Resolution of angiographic macular leakage with faricimab versus aflibercept in patients with diabetic macular edema in YOSEMITE\/RHINE. Ophthalmol Retina. 2024;9(6):515\u201326.","DOI":"10.1016\/j.oret.2024.11.015"},{"issue":"5","key":"1233_CR16","doi-asserted-by":"publisher","first-page":"100798","DOI":"10.1016\/j.xops.2025.100798","volume":"5","author":"U Chakravarthy","year":"2025","unstructured":"Chakravarthy U, Chaudhary V, Sadda SR, Tan CS, Vujosevic S, Fauser S, et al. Effect of faricimab versus aflibercept on hyperreflective foci in patients with diabetic macular edema from the YOSEMITE\/RHINE trials. Ophthalmol Sci. 2025;5(5):100798.","journal-title":"Ophthalmol Sci"},{"key":"1233_CR17","unstructured":"Singh RP. Emerging imaging and biological markers supporting Angiopoietin-2 in nAMD and DME. Presentation of the Angiogenesis, Exudation, and Degeneration 2024 Virtual Congress. 2024."},{"issue":"8","key":"1233_CR18","first-page":"3795","volume":"66","author":"S Vujosevic","year":"2025","unstructured":"Vujosevic S, Pollreisz A, Dinah C, Goldberg RA, Ip MS, Rahimy E, et al. Volumetric analysis of hard exudates on optical coherence tomography: biomarker results of faricimab vs aflibercept from the phase 3 YOSEMITE\/RHINE trials. Invest Ophthalmol Vis Sci. 2025;66(8):3795.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"1233_CR19","first-page":"2375","volume":"66","author":"JP Ehlers","year":"2025","unstructured":"Ehlers JP, Matar K, Indurkar A, Della Vecchia L, Amine R, Mamone J, et al. Quantitative ultra-widefield fluorescein angiography for the assessment of novel biomarkers of vascular stability with faricimab: a YOSEMITE\/RHINE post hoc analysis. Invest Ophthalmol Vis Sci. 2025;66(8):2375.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1233_CR20","volume":"16","author":"M Al-Rufayie","year":"2024","unstructured":"Al-Rufayie M, Palmieri F, Hamoud Bedan A, Younis S, Ali A, Kurumthottical M, et al. Real-world results in treating diabetic macular edema with faricimab at a London-based tertiary eye hospital. Cureus. 2024;16(12): e75002.","journal-title":"Cureus"},{"key":"1233_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2023.101973","volume":"33","author":"M Sawa","year":"2024","unstructured":"Sawa M, Nakagawa N, Shunto T, Nishiyama I. Two cases of diabetic macular edema with diminished areas of retinal non-perfusion and microaneurysms after intravitreal faricimab injections. Am J Ophthalmol Case Rep. 2024;33: 101973.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"1233_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/medicina59030435","volume":"59","author":"Y Takamura","year":"2023","unstructured":"Takamura Y, Yamada Y, Inatani M. Role of microaneurysms in the pathogenesis and therapy of diabetic macular edema: a descriptive review. Medicina. 2023;59(3):435.","journal-title":"Medicina"},{"issue":"6","key":"1233_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.oret.2023.01.018","volume":"7","author":"K Sarici","year":"2023","unstructured":"Sarici K, Yordi S, Martin A, Lunasco L, Mugnaini C, Chu K, et al. Longitudinal quantitative ultrawide-field fluorescein angiography dynamics in the RUBY diabetic macular edema study. Ophthalmol Retina. 2023;7(6):543\u201352.","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"1233_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.65.5.26","volume":"65","author":"EL von Schulthess","year":"2024","unstructured":"von Schulthess EL, Maunz A, Chakravarthy U, Holekamp N, Pauleikhoff D, Patel K, et al. Intraretinal hyper-reflective foci are almost universally present and co-localize with intraretinal fluid in diabetic macular edema. Invest Ophthalmol Vis Sci. 2024;65(5):26.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1233_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.oret.2025.01.017","volume":"9","author":"JI Lim","year":"2025","unstructured":"Lim JI, Amador MJ, Dhoot DS, Finn A, Fraser-Bell S, Gibson K, et al. Anatomic control with faricimab versus aflibercept in the YOSEMITE\/RHINE trials in diabetic macular edema. Ophthalmol Retina. 2025;9(7):655\u201366.","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"1233_CR26","first-page":"2401","volume":"66","author":"RP Singh","year":"2025","unstructured":"Singh RP, Zwick E, Bonine N, Leng T, Ko S, Shaia J, et al. Two-year real-world clinical outcomes in patients with diabetic macular edema treated with faricimab in the US: the FARETINA-DME study. Invest Ophthalmol Vis Sci. 2025;66(8):2401.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"1233_CR27","first-page":"3111","volume":"66","author":"RH Guymer","year":"2025","unstructured":"Guymer RH, Schmitz-Valckenberg S, Bailey C, Chaikitmongkol V, Chaudhary V, Chi G, et al. Global real-world clinical and anatomical outcomes with faricimab in treatment-na\u00efve patients with nAMD or DME from a prospective non-interventional study: the VOYAGER study. Invest Ophthalmol Vis Sci. 2025;66(8):3111.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1233_CR28","first-page":"6259","volume":"65","author":"H Khan","year":"2024","unstructured":"Khan H, Khan H, Aziz AA, Gahn G, Barakat MR, Corradetti G, et al. The real-world efficacy and safety of faricimab in diabetic macular edema: the TAHOE study. Invest Ophthalmol Vis Sci. 2024;65(7):6259.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1233_CR29","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.2147\/OPTH.S424314","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One year results of faricimab for aflibercept-resistant diabetic macular edema. Clin Ophthalmol. 2023;17:2397\u2013403.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"1233_CR30","first-page":"2388","volume":"66","author":"T Peto","year":"2025","unstructured":"Peto T, Sivaprasad S, Reynolds R, Bailey C, Downey L, Kiire C, et al. Effectiveness and safety of faricimab in eyes with DME in the United Kingdom: 1-year results from the FARWIDE-DME study. Invest Ophthalmol Vis Sci. 2025;66(8):2388.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"1233_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1167\/iovs.65.14.46","volume":"65","author":"KL Huber","year":"2024","unstructured":"Huber KL, Stino H, Steiner I, Fuchs P, Goldbach F, Mai J, et al. Real-world outcomes after switch from aflibercept to faricimab in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2024;65(14):46.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"1233_CR32","first-page":"2","volume":"9","author":"D Wong","year":"2025","unstructured":"Wong D, Chhabra R, Ruiz-Medrano J, Hamilton R. Improving clinic capacity with faricimab. EMJ Innov. 2025;9(Suppl 1):2\u201311.","journal-title":"EMJ Innov"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01233-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01233-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01233-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:42:58Z","timestamp":1760715778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01233-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01233-9","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tunde Peto: Received grant support paid to institution from Boehringer Ingelheim; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Apellis, Bayer, Boehringer Ingelheim, Heidelberg, Novartis, OPTOS, Oxurion, Roche, and Zeiss. Stela Vujosevic: Consultant for AbbVie, Adverum, Annexon, Apellis, Bayer, Boehringer Ingelheim, Novartis, Roche, and Zeiss. Veeral Sheth: Consultant for Apellis, EyePoint, Genentech, IvericBio, Kriya Therapeutics, Novartis, Ocular Therapeutix, Ocuphire, Ollin Biosciences, Opthea, Regeneron, RevOpsis, Unity, and Vial; speaker for Genentech and IvericBio; contracted research for 4D Molecular Therapeutics, AbbVie, Adverum Biotechnologies, Alimera Sciences, Ashvattha Therapeutics, Aviceda, Chengdu Kanghong, Eyebiotech, Eyepoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Ionis, IvericBio, Janssen Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Ocugen, OcuTerra, Olix, Opthea, Outlook, Oxular, Oxurion, Perfuse Therapeutics, Recens Medical, Regeneron Pharmaceuticals, RegenXBio, Rezolute, Roche, SalutarisMD, SamChungDang, Santen, Smilebiotek, Unity Biotechnology, and Vanotech. Amanda Downey: Employee of F. Hoffmann-La Roche Ltd. Kara Gibson: Employee and stockholder of Roche Products Ltd. Andreas Pollreisz: Consultant for Allergan, Bayer, Oertli Instruments, and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}